Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose Level of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Human Subjects

Inclusion criteria

• . The subject is male or female 18 to 55 years of age, inclusive
• . The subjects has a body mass index (BMI) 18 to 30 kg/m2, inclusive, at screening.
• . The subject is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead ECG results, and physical examination findings at screening.
• . The subject has a hemoglobin level within following acceptable range at Screening and Check-in: Male: 12.8 to 17.4 g/dL, Female: 10.8 to 15.0 g/dL
• . The subject has liver function tests within normal limits, or has results that do not show clinically significant abnormalities, as judged by the investigator at Screening and Check in.
• . The subject has estimated glomerular filtration rate (eGFR) ≥ 50 mL/min at Screening.
• . Female subjects of childbearing potential must use an acceptable method of birth control (i.e., diaphragm with spermicide, intrauterine device, condom with foam or vaginal spermicide, oral contraceptives, or abstinence) or be surgically sterile (i.e., hysterectomy, bilateral tubal ligation or bilateral oophorectomy), or postmenopausal (defined as amenorrhea 12 consecutive months and documented plasma FSH level \>40 IU/mL). Female subjects must have a negative pregnancy test at screening and before dosing with study drug.
• . The subject agrees to comply with all protocol requirements.

Exclusion criteria